Longterm therapeutic benefit of infliximab/DMARD combination in inflammatory arthritis: comparative analysis of 8 year data

被引：0
|
作者：
Harty, L. C. [1 ]
Veale, D. J. [1 ]
机构：
[1] St Vincents Univ Hosp, Dept Rheumatol, Dublin 4, Ireland
来源：
IRISH JOURNAL OF MEDICAL SCIENCE | 2012年 / 181卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：65 / 66
页数：2
相关论文
共 10 条
  • [1] Two-year data: Infliximab maintains clinical response in psoriatic arthritis patients - An analysis of the year 2 data from the infliximab multinational psoriatic arthritis controlled trial (impact)
    Antoni, CE
    Kavanaugh, A
    Kirkham, B
    Tutuncu, Z
    Burmester, GR
    Schneider, U
    Furst, DE
    Molitor, J
    Keystone, E
    Gladman, D
    Manger, B
    Wassenberg, S
    Weier, R
    Wallace, D
    Weisman, MH
    Kalden, JR
    Smolen, J
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 82 - 82
  • [2] Persistence on biologic DMARD monotherapy after achieving rheumatoid arthritis disease control on combination therapy: retrospective analysis of corrona registry data
    Dimitrios A. Pappas
    Heather J. Litman
    Tamara Lesperance
    Greg Kricorian
    Elaine Karis
    Sabrina Rebello
    Winnie Hua
    Neil A. Accortt
    Scott Stryker
    [J]. Rheumatology International, 2021, 41 : 381 - 390
  • [3] Persistence on biologic DMARD monotherapy after achieving rheumatoid arthritis disease control on combination therapy: retrospective analysis of corrona registry data
    Pappas, Dimitrios A.
    Litman, Heather J.
    Lesperance, Tamara
    Kricorian, Greg
    Karis, Elaine
    Rebello, Sabrina
    Hua, Winnie
    Accortt, Neil A.
    Stryker, Scott
    [J]. RHEUMATOLOGY INTERNATIONAL, 2021, 41 (02) : 381 - 390
  • [4] Comparative efficacy and safety of biosimilar-infliximab and originator-infliximab in combination with methotrexate in patients with active rheumatoid arthritis: a meta-analysis of randomized controlled trials
    Bae, Sang-Cheol
    Lee, Young Ho
    [J]. INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2018, 21 (05) : 922 - 929
  • [5] Brucellar arthritis and sacroiliitis: an 8-year retrospective comparative analysis of demographic, clinical, and paraclinical features
    Morovati, Sanaz
    Bozorgomid, Arezoo
    Mohammadi, Arman
    Ahmadi, Forouzan
    Arghand, Leila
    Shadmani, Fatemeh Khosravi
    Sayad, Babak
    [J]. THERAPEUTIC ADVANCES IN INFECTIOUS DISEASE, 2024, 11
  • [6] IS MENTAL HEALTH COMPARABALE IN RHEUMATOID AND PSORIATIC ARTHRITIS PATIENTS? A COMPARATIVE ANALYSIS OF REAL LIFE LONGITUDINAL DATA FROM THE NOR-DMARD STUDY
    Michelsen, B.
    Lie, E.
    Fagerli, K. M.
    Kristianslund, E. K.
    Hammer, H. B.
    Haugeberg, G.
    Kvien, T. K.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 97 - 98
  • [7] Analysis of Trial Data for Infliximab and Golimumab: Baseline C-Reactive Protein Level and Prediction of Therapeutic Response in Patients With Psoriatic Arthritis
    Au, Shiu-Chung
    Ramirez-Fort, Marigdalia K.
    Gottlieb, Alice B.
    [J]. ARTHRITIS CARE & RESEARCH, 2014, 66 (07) : 1114 - 1118
  • [8] A prospective one year randomized comparative clinical and MRI study of the effects of methotrexate (MTX) alone or in combination with infliximab (IFX) or intravenous (IV) pulse methylprednisolone (MP) in early rheumatoid arthritis (RA)
    Durez, P.
    Malghem, J.
    Toukap, A. Nzeusseu
    Depresseux, G.
    Lauwerys, B. R.
    Westhovens, R.
    Luyten, F. P.
    Houssiau, F. A.
    Verschueren, P.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 54 - 55
  • [9] Enhancing Therapeutic Drug Monitoring in Inflammatory Bowel Disease: A Comparative Analysis of Rapid Point-of-Care Infliximab, Adalimumab and Anti-Drug Antibodies' Determination against ELISA
    Toja-Camba, Francisco Jose
    Garcia-Quintanilla, Laura
    Rodriguez-Martinez, Lorena
    Tomine, Julia
    Cajade-Pascual, Francisco
    Feitosa, Carolina
    Zarra-Ferro, Irene
    Barreiro-De-Acosta, Manuel
    Gonzalez-Lopez, Jaime
    Mondelo-Garcia, Cristina
    Fernandez-Ferreiro, Anxo
    [J]. PHARMACEUTICS, 2023, 15 (11)
  • [10] Nimotuzumab in combination with chemoradiation for patients with intermediate stage and locally advanced nasopharyngeal carcinoma: A retrospective comparative analysis using 5-year real-world survival data
    Rachman, A.
    Sari, S. R.
    Adham, M.
    Munandar, A.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S1615 - S1616
1